- ►annals.org LK Khan, MK Serdula, BA Bowman, DF … - Annals of internal medicine, 2001 - Am Coll Physicians Background: Pharmacotherapy is recommended for the treatment of obese persons
with a body mass index of 30 kg/m 2 or higher or a body mass index of at least
27 kg/m 2 plus an obesity-related comorbid condition. Cited by 57 - Related articles - BL Direct - All 6 versions
[CITATION] Valvular heart disease induced by anorectic drugs
WH Gaasch, GP Aurigemma - UpToDate (serial on CD-ROM. 8/3. 2003. UpToDate, … Cited by 9 - Related articles
JD Little, SE Romans - International clinical psychopharmacology, 1993 - journals.lww.com The case of an organic psychosis following the readministration of an
amphetamine-like anorexiant is described. Previous therapeutic use of the same
drug 2 years earlier was without adverse effect. Similar phenomena have ... Cited by 16 - Related articles - BL Direct - All 4 versions
M Hagiwara, A Tsuchida, M Hyakkoku, K … - Jpn Circ J, 2000 - sciencelinks.jp Abstract;The use of the appetite suppressant agents aminorex and fenfluramine
derivatives has been reported as a risk factor for the development of pulmonary
hypertension. A 29-year-old female developed pulmonary hypertension ... Cited by 17 - Related articles - Cached - BL Direct - All 5 versions
- ►bmj.com [PDF] SH Thomas, AY Butt, PA Corris, JJ Egan, TW … - British Medical Journal, 1995 - heart.bmj.com Abstract Objective-Amphetamine-like appetite suppressants, particularly
fenfluramines, have been implicated in the aetiology of primary pulmonary
hypertension. At one specialist centre in France 20% ofpatients with ... Cited by 36 - Related articles - BL Direct - All 7 versions
RS Stafford, DC Radley - Archives of Internal Medicine, 2003 - Am Med Assoc Results At its peak in the second quarter of 1997, 2.5 million Americans were
taking antiobesity medications, a 4-fold increase over the prior 2 years.
Although antiobesity medication use diminished following the market exit of ... Cited by 59 - Related articles - BL Direct - All 5 versions
WS Poston 2nd, JP Foreyt - Texas medicine, 2000 - ncbi.nlm.nih.gov Fenfluramine and dexfenfluramine were popular and widely used antiobesity agents
until they were withdrawn from the market in 1997. Even though early research
appeared to demonstrate their safety, serious concerns were raised about ... Cited by 11 - Related articles
[CITATION] Mazindol in obesity with known cardiac disease
TA Wadden, RI Berkowitz, LG Womble, DB … - Obesity, 2000 - nature.com Research Methods and Procedures: Patients were 34 women with a mean age of 44.1
10.4 years, weight of 89.4 13.8 kg, and body mass index (BMI) of 33.9 4.9 kg/m 2
who had lost an average of 11.6 9.2% of initial weight during the prior 1 ... Cited by 112 - Related articles - BL Direct - All 2 versions
